Telo Genomics Launches a Commercial Evaluation of Applied Spectral Imaging Automation (AI) with TELO Workflow
September 14 2020 - 9:15AM
Telo Genomics Corp. (TSX-V: TELO) (the
“Company” or
“TELO”) is pleased
to announce that it has launched a commercial evaluation in
collaboration with Applied Spectral Imaging (ASI) California to
assess the applicability of integrating GenASIs™, the ASI automated
imaging and analysis solutions into TELO’s workflow.
The assessment focuses on processing and
comparing analysis results of identical samples achieved using ASI
GenASIs™ HiFISH automation solution and the traditional TELO’s
workflow
The potential integration of ASI GenASIs™
automation and image analysis solutions into TELO’s workflow
targets to augment the efficiency and consistency of TELO’s
workflow, and at the same time decrease the laboratory’s processing
time (Turnaround Time) and cost. The added value has the potential
to expedite the adoption of TELO’s technology in the clinic. Future
directions for the collaboration between ASI and Telo will be
defined based on the compatibility and concordance of the two
workflows.
“I look forward to the promising results from
this assessment in partnership with ASI. ASI offers world class
automation solutions, and has been a long-term collaborator”, said
Sabine Mai, TELO’s co-Founder, Director and Chair of the Clinical
and Scientific Advisory Board.
“We are excited to launch this assessment with
Telo Genomics, we trust ASI technology will offer added value to
TELO’s workflow. ASI GenASIs™ solutions gained several FDA
clearances for diagnostic and prognostic tests already in the
clinic”, said Limor Shiposh, ASI CEO.
About Telo Genomics
Telo Genomics is a biotech company pioneering
the most comprehensive telomere platform in the industry with
powerful applications and prognostic solutions. These include
liquid biopsies and related technologies in oncology and
neurological diseases. Liquid biopsy is a rapidly growing field of
significant interest to the medical community for being less
invasive and more easily replicated than traditional diagnostic
approaches. By combining our team’s considerable expertise in
quantitative analysis of 3D telomeres with molecular biology and
artificial intelligence to recognize disease-associated genetic
instability, Telo Genomics is developing simple and accurate
products that improve day-to-day care for patients by serving the
needs of pathologists, clinicians, academic researchers and drug
developers. The benefits of our proprietary technology have been
substantiated in over 150 peer reviewed publications and in 25
clinical studies involving more than 3,000 patients with multiple
cancers and Alzheimer’s disease. Our lead application, Telo-MM is
being developed to provide important, actionable information to
medical professionals in the treatment of Multiple Myeloma, a
deadly form of blood cancer.
About Applied Spectral
Imaging
ASI is a global leader and provider of
biomedical imaging and analysis solutions with a comprehensive
product portfolio in digital diagnostics. Founded in 1993, ASI
markets, services, and supports its products in more than 50
countries. The company has worldwide offices in the US and Asia,
plus a global network of distribution partners.
For more information about ASI’s products and
clinical applications, please visit the company’s website at
https://spectral-imaging.com/
For further information, please
contact:
Hugh
RogersDirector416-673-8487info@telodx.com MaRS Centre, South
Tower, 101 College Street, Suite 200, Toronto, ON, M5G
1L7www.telodx.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as such term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding
Forward-Looking Statements
Certain information contained herein may
constitute “forward-looking information” under Canadian securities
legislation. Generally, forward-looking information can be
identified by the use of forward-looking terminology such as
“intends”, “will”, or variations of such words and phrases or
statements that certain actions, events or results “will” occur.
Forward-looking statements regarding the clinical efficacy of
products, commercial viability of products, use of proceeds, and
the ability of the TeloViewTM platform to deliver personalized
medicine resulting in better treatments and outcomes are based on
the Company’s estimates and are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information,
including capital expenditures and other costs. There can be no
assurance that such statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on forward- looking statements and
forward-looking information. The Company will not update any
forward-looking statements or forward-looking information that are
incorporated by reference herein, except as required by applicable
securities laws.
Telo Genomics (TSXV:TELO)
Historical Stock Chart
From Nov 2024 to Dec 2024
Telo Genomics (TSXV:TELO)
Historical Stock Chart
From Dec 2023 to Dec 2024